Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to -$2.2 million.

  • OptimizeRx's Change in Accured Expenses fell 93333.33% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 51255.2%. This contributed to the annual value of $1.1 million for FY2024, which is 1918.65% down from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Change in Accured Expenses is -$2.2 million, which was down 93333.33% from $3.3 million recorded in Q2 2025.
  • OptimizeRx's 5-year Change in Accured Expenses high stood at $3.3 million for Q2 2025, and its period low was -$2.2 million during Q3 2025.
  • In the last 5 years, OptimizeRx's Change in Accured Expenses had a median value of $267000.0 in 2024 and averaged $234216.3.
  • In the last 5 years, OptimizeRx's Change in Accured Expenses soared by 601064.61% in 2023 and then plummeted by 93333.33% in 2025.
  • OptimizeRx's Change in Accured Expenses (Quarter) stood at $536185.0 in 2021, then skyrocketed by 74.63% to $936323.0 in 2022, then decreased by 15.2% to $794000.0 in 2023, then skyrocketed by 284.13% to $3.0 million in 2024, then plummeted by 172.95% to -$2.2 million in 2025.
  • Its last three reported values are -$2.2 million in Q3 2025, $3.3 million for Q2 2025, and $854000.0 during Q1 2025.